AU Patent

AU2011224275B2 — Oral formulations and lipophilic salts of methylnaltrexone

Assigned to Wyeth LLC · Expires 2015-10-01 · 11y expired

What this patent protects

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

USPTO Abstract

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

Drugs covered by this patent

methylnaltrexone-bromide (METHYLNALTREXONE BROMIDE)

Patent Metadata

Patent number: AU2011224275B2
Jurisdiction: AU
Classification: —
Expires: 2015-10-01
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.